CN Patent

CN114632088B — 阿糖胞苷化合物在制备治疗脊髓胶质瘤的药物中的用途

Assigned to Beijing Neurosurgical Institute · Expires 2022-08-16 · 4y expired

What this patent protects

本发明提供了阿糖胞苷在制备治疗脊髓胶质瘤的药物中的用途。本发明通过施用阿糖胞苷化合物，在细胞水平上能够有效的抑制阿糖胞苷的细胞增殖，呈明显的剂量依赖性；在动物模型水平上能够有效地抑制荷瘤小鼠的肿瘤生长并延长荷瘤小鼠的生存周期。因此本发明通过施用阿糖胞苷化合物，为H3K27M突变型脊髓胶质瘤的治疗提供了一种新的解决方案。

USPTO Abstract

本发明提供了阿糖胞苷在制备治疗脊髓胶质瘤的药物中的用途。本发明通过施用阿糖胞苷化合物，在细胞水平上能够有效的抑制阿糖胞苷的细胞增殖，呈明显的剂量依赖性；在动物模型水平上能够有效地抑制荷瘤小鼠的肿瘤生长并延长荷瘤小鼠的生存周期。因此本发明通过施用阿糖胞苷化合物，为H3K27M突变型脊髓胶质瘤的治疗提供了一种新的解决方案。

Drugs covered by this patent

dordaviprone-hydrochloride (DORDAVIPRONE HYDROCHLORIDE)

Patent Metadata

Patent number: CN114632088B
Jurisdiction: CN
Classification: —
Expires: 2022-08-16
Drug substance claim: No
Drug product claim: No
Assignee: Beijing Neurosurgical Institute
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.